Study of vitamin D3 level in Egyptian hemodialysis patients and the effect of replacement therapy

A. Sabry, M. Elazazy, Ahmed Mohammed Abd El Wahab
{"title":"Study of vitamin D3 level in Egyptian hemodialysis patients and the effect of replacement therapy","authors":"A. Sabry, M. Elazazy, Ahmed Mohammed Abd El Wahab","doi":"10.56391/jnrm.2022.1015","DOIUrl":null,"url":null,"abstract":"Background The ability of extrarenal tissues to convert 25-hydroxyvitamin D into 1,25-hydroxyvitamin D and its dependence on substrate levels provide the rationale for supplementing vitamin D in dialysis patients who usually have severe depletion of both calcitriol and vitamin D. The primary aim of the study was to detect serum vitamin D3 levels in a cohort of Egyptian hemodialysis patients and to check the effect of 12-week therapy of cholecalciferol on serum calcium, phosphate, and parathyroid hormone (PTH) in vitamin D-naïve hemodialysis patients with vitamin D deficiency. Patients and methods A total of 40 patients (25 males and 15 females) with chronic kidney disease on regular hemodialysis, attending the Nephrology Unit of internal Medicine Department, Mansoura University Hospital, during the period from January to June 2017, were included. According to laboratory investigations and clinical examination, deficient patients were treated with Devarol-S (cholecalciferol) for 3 months and then revaluated. Deficient patients received intramuscular injection of 50 000 IU monthly for 3 consecutive months. Results The patient group included 40 persons, comprising 27 (73%) male patients and 13 (27%) female patients. Their mean age was 47.16 ± 14.92 years. The mean dialysis duration was 4.68 ± 2.42 years. At 3 months after vitamin D replacement, significant increase in serum calcium (8.33–8.89 mg/dl), phosphorous (4.99–5.85 mg/dl), and vitamin D3 (4.01–28.43 ng/ml) levels were observed compared with pretreatment levels. There was also significant decrease in PTH level (419.30–377.20 pg/ml). After 3 months of follow-up, there were no significant changes in the levels of hemoglobin, Kt/v, albumin, and alkaline phosphatase in the study group. Conclusions In most patients, treatment with cholecalciferol in a 50 000 IU/month dose permits safe correction of vitamin D deficiency and control of PTH level, yet serum phosphorus should be monitored.","PeriodicalId":285751,"journal":{"name":"Journal of The Egyptian Society of Nephrology and Transplantation","volume":"1032 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of The Egyptian Society of Nephrology and Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56391/jnrm.2022.1015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background The ability of extrarenal tissues to convert 25-hydroxyvitamin D into 1,25-hydroxyvitamin D and its dependence on substrate levels provide the rationale for supplementing vitamin D in dialysis patients who usually have severe depletion of both calcitriol and vitamin D. The primary aim of the study was to detect serum vitamin D3 levels in a cohort of Egyptian hemodialysis patients and to check the effect of 12-week therapy of cholecalciferol on serum calcium, phosphate, and parathyroid hormone (PTH) in vitamin D-naïve hemodialysis patients with vitamin D deficiency. Patients and methods A total of 40 patients (25 males and 15 females) with chronic kidney disease on regular hemodialysis, attending the Nephrology Unit of internal Medicine Department, Mansoura University Hospital, during the period from January to June 2017, were included. According to laboratory investigations and clinical examination, deficient patients were treated with Devarol-S (cholecalciferol) for 3 months and then revaluated. Deficient patients received intramuscular injection of 50 000 IU monthly for 3 consecutive months. Results The patient group included 40 persons, comprising 27 (73%) male patients and 13 (27%) female patients. Their mean age was 47.16 ± 14.92 years. The mean dialysis duration was 4.68 ± 2.42 years. At 3 months after vitamin D replacement, significant increase in serum calcium (8.33–8.89 mg/dl), phosphorous (4.99–5.85 mg/dl), and vitamin D3 (4.01–28.43 ng/ml) levels were observed compared with pretreatment levels. There was also significant decrease in PTH level (419.30–377.20 pg/ml). After 3 months of follow-up, there were no significant changes in the levels of hemoglobin, Kt/v, albumin, and alkaline phosphatase in the study group. Conclusions In most patients, treatment with cholecalciferol in a 50 000 IU/month dose permits safe correction of vitamin D deficiency and control of PTH level, yet serum phosphorus should be monitored.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
埃及血液透析患者维生素D3水平及替代治疗效果的研究
肾外组织将25-羟基维生素D转化为1,25-羟基维生素D的能力及其对底物水平的依赖性为通常骨化三醇和维生素D严重缺乏的透析患者补充维生素D提供了依据。本研究的主要目的是检测埃及血液透析患者队列中血清维生素D3水平,并检查12周胆骨化醇治疗对血清钙、磷酸盐、和甲状旁腺激素(PTH)在维生素D-naïve缺乏症血液透析患者中的作用。患者与方法选取2017年1 - 6月在曼苏拉大学附属医院内科肾内科定期进行血液透析的慢性肾病患者40例(男25例,女15例)。根据实验室调查和临床检查,缺陷患者给予德伐罗- s(胆骨化醇)治疗3个月,然后重新评估。缺陷患者每月肌注5万IU,连续3个月。结果本组共40例患者,其中男性27例(73%),女性13例(27%)。平均年龄47.16±14.92岁。平均透析时间为4.68±2.42年。在维生素D替代3个月后,血清钙(8.33-8.89 mg/dl)、磷(4.99-5.85 mg/dl)和维生素D3 (4.01-28.43 ng/ml)水平显著高于预处理水平。PTH水平明显降低(419.30 ~ 377.20 pg/ml)。随访3个月后,研究组血红蛋白、Kt/v、白蛋白、碱性磷酸酶水平无明显变化。结论在大多数患者中,以5万IU/月剂量的胆骨化醇治疗可以安全纠正维生素D缺乏症和控制甲状肾上腺素水平,但仍应监测血清磷。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Current approaches in managing pregnancy in kidney transplant recipients Clinicopathologic features, chronic renal damage, and short-term outcomes of glomerular diseases in a middle east tertiary care center Urinary heme oxygenase-1 as a possible marker for early diagnosis of diabetic nephropathy and retinopathy Expression profile of HLA-DRB1, RFX5, and CIITA promoters in chronic kidney disease patients from South India Fibronectin type-III domain-containing protein 5 genetic polymorphism and serum irisin-level change in relation to type-2 diabetes mellitus with diabetic nephropathy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1